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Abstract
Background: Clinical practice guidelines (CPGs) are developed to assist health
care providers in decision-making. We systematically reviewed existing CPGs on
the HDPs (hypertensive disorders of pregnancy) to inform clinical practice.
Methodology & Principal Findings: MEDLINE, EMBASE, Cochrane Central
Register of Controlled Trials, Cochrane Methodology Register, Health Technology
Assessments, and Database of Abstracts of Reviews of Effects (Ovid interface),
Grey Matters, Google Scholar, and personal records were searched for CPGs on
the HDPs (Jan/03 to Nov/13) in English, French, Dutch, or German. Of 13 CPGs
identified, three were multinational and three developed for community/midwifery
use. Length varied from 3–1188 pages and three guidelines did not formulate
recommendations. Eight different grading systems were identified for assessing
evidence quality and recommendation strength. No guideline scored §80% on
every domain of the AGREE II, a tool for assessing guideline methodological
quality; two CPGs did so for 5/6 domains. Consistency was seen for (i) definitions of
hypertension, proteinuria, chronic and gestational hypertension; (ii) pre-eclampsia
prevention for women at increased risk: calcium when intake is low and low-dose
aspirin, but not vitamins C and E or diuretics; (iii) antihypertensive treatment of
severe hypertension; (iv) MgSO4 for eclampsia and severe pre-eclampsia;
(v) antenatal corticosteroids at ,34 wks when delivery is probable within 7 days;
(vi) delivery for women with severe pre-eclampsia pre-viability or pre-eclampsia at
term; and (vii) active management of the third stage of labour with oxytocin. Notable
inconsistencies were in: (i) definitions of pre-eclampsia and severe pre-eclampsia;
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(ii) target BP for non-severe hypertension; (iii) timing of delivery for women with pre-
eclampsia and severe pre-eclampsia; (iv) MgSO4 for non-severe pre-eclampsia,
and (v) postpartum maternal monitoring.
Conclusions: Existing international HDP CPGs have areas of consistency with
which clinicians and researchers can work to develop auditable standards, and
areas of inconsistency that should be addressed by future research.
Introduction
The hypertensive disorders of pregnancy (HDPs) are common, complicating up
to 6–8% of all pregnancies. As such, the HDPs are a leading cause of maternal and
perinatal mortality and morbidity, worldwide. It is anticipated that this situation
will only worsen, given the rising prevalence of obesity and metabolic syndrome
among women of childbearing age [1–2].
Many national and international clinical practice guidelines (CPGs) have been
published on the diagnosis, evaluation, and management of the HDPs. Although
many such CPGs have quoted the same research papers, the between-guideline
variability in specific recommendations has been highlighted by international
multicentre research endeavours, such as the CHIPS Trial (Control of
Hypertension In Pregnancy Study) [3]. However, no analysis of CPG quality and
consistency has been achieved as for other conditions [4–9]. In addition,
substandard care of women with pregnancy hypertension, especially failures
related to diagnosis, evaluation, and management, continues to be recognised as a
contributor to maternal death in well- [10–11] and less-resourced settings [12].
We sought to review published CPGs covering the diagnosis, evaluation, and
management of the HDPs, in order to inform practicing clinicians about the
consistency of the recommendations and the quality of the source guidelines.
Methods
Eligibility
Included were multi-disciplinary CPGs that were: (i) published within the last 10
years (2003–13), and the then accepted 2014 SOGC guideline (now published)
[30, 31], (ii) covered the diagnosis, assessment and management of one/more of
the HDPs in human pregnancy, and (iii) were written in English, French, Dutch
or German (i.e., languages understood by the review authors). Excluded were
CPGs that: were adapted for local use from an existing CPG, had no references, or
were not regional/national/international in scope.
HDP: Systematic Review of International CPGs
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Literature search
A comprehensive literature review was undertaken by a librarian (KM) of the
College of Physicians and Surgeons of British Columbia, in consultation with the
principal authors of this article. Key words, related to hypertension, pregnancy,
and guidelines, were used to search MEDLINE, EMBASE, Cochrane Central
Register of Controlled Trials, Cochrane Methodology Register, Health Technology
Assessments, and Database of Abstracts of Reviews of Effects using the Ovid
interface (Appendix S1). As not all CPGs may be available on bibliographic
databases cited above, additional sources were searched including personal
records. Grey Matters, a tool for evidence-based searching on the internet
developed by the Canadian Agency for Drugs and Technologies in Health, was
used to locate online grey literature sources, which were searched using key words
such as ‘‘hypertensive disorders of pregnancy’’, ‘‘gestational hypertension’’,
‘‘hypertension during pregnancy’’, ‘‘pregnancy induced hypertension’’, and
‘‘hypertension gestationnelle’’; this site includes the National Guidelines
Clearinghouse. Similar search terms combined with ‘‘guideline’’ or ‘‘recommen-
dation’’ were entered on Google Scholar and the first 100 results were screened,
considering most relevant results appear first. Finally, the national websites of
societies of obstetrics and gynaecology of the main French-, English-, Dutch- or
German-speaking countries were searched.
Processing data
The AGREE II tool was used to assess the methodological quality of all included
CPGs [13]. Using the standardised AGREE II methodology, scores of 1 to 7 were
given both overall and to each of 23 items in six domains related to standard
methodology. Percentages of maximum possible scores were calculated for each
domain. Also, each reviewer responded to the following question, ‘‘I would
recommend this guideline for use’’ with ‘yes’, ‘yes with modifications’ and ‘no’.
For this review, ‘yes’ was given to a guideline considered useful as a reference
document for busy clinicians as such, ‘no’ was assigned to CPGs that did not
formulate recommendations (but consisted of text only). Two authors (TG, AP,
and/or LM) rated each CPG independently and discrepancies were resolved by
consensus.
Descriptive analyses were undertaken to present the general characteristics of
each CPG, including the grading system used to assess the quality of evidence and
strength of recommendations. For all CPGs recommended for use, we examined:
(i) criteria for diagnosis and HDP classification, using information from the tables
and text as diagnostic criteria do not lend themselves well to recommendations,
and (ii) recommendations about ‘actionable items’ related to prevention of pre-
eclampsia or management of any HDP, that were reported commonly (by at least
three CPGs) and/or designated to have a high rating for quality of evidence and
strength of recommendation.
This was an analysis of published data and did not require research ethics board
approval.
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Results
Literature search and guideline selection
Figure 1 shows that our search strategy yielded 189 records for consideration, 132
from database searches and 57 identified through other sources. Following
screening and review of full text papers, 16 articles were excluded [14–29] and
there were 13 CPGs for inclusion in addition to the 2014 ISSHP position
statement.
Guideline characteristics
Table 1 presents general characteristics of the included CPGs, developed in
Canada (Society of Obstetricians and Gynaecologists of Canada (SOGC),
Association of Ontario Midwives (AOM)) [30–32], the United Kingdom
(National Institute for Health and Clinical Excellence (NICE), pre-eclampsia
community guideline (PRECOG), PRECOG II) [33–35], the United States of
America (American College of Obstetricians and Gynecologists (ACOG),
American Society of Hypertension (ASH)) [36–37], Australia (Queensland
Maternity and Neonatal Clinical Guidelines Program (QLD)) [38–39], the
Figure 1. Search results.
doi:10.1371/journal.pone.0113715.g001
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Netherlands (Nederlandse Vereniging voor Obstetrie en Gynaecologie (NVOG))
[40], and Germany (Deutschen Gesellschaft fur Gynakologie und Geburtshilfe
(DGGG)) [41]. Most CPGs were national (8/13), but three were multinational,
from Australasia (Society of Obstetric Medicine of Australia and New Zealand
(SOMANZ)) [42], the World Health Organization (WHO) [43], and the
European guideline for cardiovascular diseases (ESC) [44]. Most CPGs (8/13)
were new, but five were updates of previous CPGs published 6–13 yr prior. All but
two guidelines [NICE, WHO] had professional organizations behind them. The
number of pages (including appendices) varied from 3 [PRECOG II] to 1188
[NICE] and the number of recommendations from 7–150 in the 10 CPGs that
made formal recommendations. Three CPGs [PRECOG, PRECOG II, AOM] were
written specifically for community [PRECOG, AOM] or hospital-based
[PRECOG II] midwifery care.
All CPGs covered pre-existing (chronic) hypertension, gestational hyperten-
sion, and preeclampsia, with the exception of the WHO guideline that focused
only on pre-eclampsia and eclampsia. Six CPGs mentioned white coat
Table 1. General description of included Clinical Practice Guidelines.
Domain and
sub-questions PRECOG* DGGG SOMANZ
ASH
PRECOG
II* QLD NICE WHO ESC NVOG AOM* ACOG SOGC
2005 2007 2008 2008 2009 2010 2010 2011 2011 2011 2012 2013 2014
Status of the CPG
New ! – ! ! ! ! ! ! ! – – – –
Update of previous – ! – – – – – – – ! ! ! !
N yr since prior CPG – 6 6 11 13 6
Level of development
International ! ! ! –
National ! ! ! ! ! ! ! !
Regional ! ! –
Organization
behind CPG
Professional ! ! ! ! ! ! ! ! ! ! !
Government !
Other !
Usability
N pages 5 16 31 12 3 32 1188 40 51 103 46 100 63
Body of document 5 16 31 12 3 19 216 33 4 66 46 100 40
Appendices – 0 0 0 0 13D 972 7 0 37 – – 23{
N references 24 260 161 69 17 20 277 34 254 1051 136 3281 535
N recommendations ?¤ 0 0 0 27 11 123 23 7 17 19 60 150
Funding stated ! – – – ! ! ! ! ! ! ! – !
*Guidelines developed for community/midwifery use, D The supplement was considered as an appendix, { The executive summary was regarded as an
appendix, 1 Represents all references for all chapters and includes duplicates, ¤ Recommendations presented in 3 boxes and 2 tables.
doi:10.1371/journal.pone.0113715.t001
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hypertension [SOMANZ, QLD, NICE, AOM, ACOG, SOGC]. Only SOGC
mentioned reversed white coat effect [SOGC].
Assessment of the evidence and strength of recommendations
Two CPGs did not grade the quality of evidence [SOMANZ, ASH]. Table 2 shows
that the other 10 CPGs used eight different systems to grade the quality of the
evidence: GRADE (N53) [WHO, SOGC, ACOG], the Canadian Task Force on
Preventive Health Care (N53) [SOGC, AOM, QLD], or a novel system (N54)
[ESC, DGGG, PRECOG and PRECOG II, NICE and NVOG], two of which
classified diagnostic accuracy and intervention studies using different criteria
[NICE, NVOG]. SOGC used both GRADE and the Canadian Task Force on
Preventive Health Care. Meta-analysis of randomised controlled trials (RCTs) was
rated among the highest quality evidence by all but the Canadian Task Force on
Preventive Health Care which does not mention this study design. The rating used
by NICE had three levels of high quality evidence, whereas most other systems had
one. All systems included expert opinion or consensus among the lowest quality
of evidence, although two systems included descriptive studies as well (PRECOG,
and PRECOG II; Canadian Task Force on Preventive Health Care).
Table 3 shows that the strength of the recommendations was presented by
seven CPGs using four approaches: GRADE (N53) [WHO, SOGC, ACOG], the
Canadian Task Force on Preventive Health Care (N53) [SOGC, AOM, QLD], or
a novel system (N52) [ESC, PRECOG and PRECOG II]; SOGC used both
GRADE and the Canadian Task Force on Preventive Health Care.
Two guidelines rated neither the quality of evidence nor the strength of their
recommendations [SOMANZ, ASH]. Two CPGs rated the quality of evidence
without rating the strength of their recommendations [NICE, NVOG], and one
rated evidence discussed in the text without making recommendations [DGGG].
Scope of the guidelines
All CPGs covered pre-existing (chronic) hypertension, gestational hypertension,
and preeclampsia, with the exception of the WHO guideline that focused only on
pre-eclampsia and eclampsia. Five CPGs mentioned white coat hypertension
[SOMANZ, QLD, AOM, ACOG, SOGC]. Only SOGC mentioned reversed white
coat effect [SOGC].
AGREE II scoring
The AGREE II scores for each CPG are presented in Table 4. The highest scores
(§80%) were obtained for the domains ‘scope and purpose’ (N55 CPGs)
[PRECOG, QLD, NICE, WHO, SOGC] and ‘clarity of presentation’ (N56)
[NICE, WHO, NVOG, AOM, ACOG, SOGC] for which three CPGs with text only
had low scores [ASH, DGGG, SOMANZ]. The lowest scores were obtained in the
domains of: (i) ‘applicability’ (as only one CPG met most criteria for presenting
facilitators and barriers for CPG implementation [WHO] and only three listed
HDP: Systematic Review of International CPGs
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auditing or monitoring criteria [SOMANZ, NICE, WHO]), (ii) ‘editorial
independence’ (as most CPGs were funded/initiated by professional organisations
and only three CPGs stated that the funding body had not influenced CPG
content [PRECOG II, NVOG, AOM]), and (iii) ‘stakeholder involvement’ because
the views and preferences of the target population were usually not represented.
No CPG achieved§80% of the maximal score for all six domains, but the WHO
and NICE guidelines did so for 5/6 domains. Four guidelines did not obtain one
score §80% in any domain [ASH, DGGG, ESC, SOMANZ]; these same CPGs
were also rated as not being clinically useful. As such, the HDP classification and
recommendations regarding prevention and treatment are described for the
remaining nine guidelines.
Definitions/classification (Tables S1 and S2)
Hypertension is defined according to systolic and diastolic BP (§140/90 mmHg)
(N55) [QLD, NICE, NVOG, ACOG, SOGC], diastolic BP alone (§90 mmHg)
Table 2. Grading systems for assessing the levels of evidence*.
PRECOG
PRECOG II
DGGG
Canadian Task
Force For
Preventive
Health
Care
NICE (intervention
studies)
NICE
(accuracy of
diagnostic
tests) ESC
NVOG
(methodological
quality of studies)
NVOG
(level of
evidence
of conclusions) GRADE
Highest
possible
level
Ia (meta-ana-
lysis of RCTs)
I{ (1 or more
RCT)
1++ (very low risk
bias meta-analysis
or
systematic review
of RCTs or RCTs)
Ia (systematic
review of
level-1 stu-
dies)
A (meta-
analysis
of RCTs or
RCTs)
A1 (systematic
reviews or
meta-analysis of
RCTs)
1 (1 systematic
review or
meta-analysis of
RCTs, or 2 RCTs)
High
Ib (1 or more
RCT)
1+ (low risk bias
meta-analysis or
systematic review
of RCTs or RCTs)
A2 (RCTs)
12 (high risk bias
meta-analysis or
systematic review
of RCTs or RCTs)
IIa II-1 2++ Ib B B 2 Moderate
IIb II-2 2+ II 3 Low
II-3 22 III
Lowest
possible
level
III (non-experi-
mental
descriptive stu-
dies)
3 (non-analytical
studies)
C (non-comparative
studies)
IV (Expert
report/opinion)
III (Expert report/
opinion)
4 (Expert consen-
sus/opinion)
IV (Expert con-
sensus/opi-
nion)
C{ (Expert
opinion, small
studies, retro-
spective stu-
dies)
D (Expert opinion) 4 (Expert opinion) Very low
*Bold indicates comparable gradings for ‘high quality’ evidence. Italic indicates comparable shading for ‘low quality’ evidence.
{Does NOT include meta-analysis of RCTs.
{includes small studies and retrospective studies as well.
doi:10.1371/journal.pone.0113715.t002
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(N53) [PRECOG, PRECOG II, AoM], or not at all (N51) [WHO] (Table S1).
Severe hypertension is defined in 7/9 CPGs, as BP§160/110 mmHg (N56)
[NICE, QLD, NVOG, AOM, ACOG, SOGC] or§170/110 mmHg [PRECOG II].
Screening for proteinuria is specifically advocated only by four CPGs for
women with a HDP [AOM, NICE, PRECOG, SOGC]; when performed, testing
methods should be by dipstick (visual [PRECOG, AOM], automated [NICE], or
either [SOGC]), but NICE advocates using a random urine protein:creatinine
ratio (PrCr) in a secondary care setting [NICE] (Table S1). Significant thresholds
for proteinuria are: §1+ [PRECOG, SOGC] or §2+ [PRECOG II, QLD], with
two CPGs specifying that a threshold of §1+ should be used only when there is
associated hypertension [PRECOG II] or other manifestations of pre-eclampsia
[AOM].
For quantification of proteinuria, criteria are: ‘‘dipstick’’§1+ [AOM], random
urine PrCr §30 mg/mmol [PRECOG, PRECOG II, NICE, SOGC], and/or 24 hr
urinary protein §0.3 g/d [PRECOG, PRECOG II, NICE, NVOG, ACOG SOGC]
(with completeness of the urine collection emphasised by two CPGs [NICE,
SOGC]).
There is consistency with regards to the definitions of chronic (pre-existing)
and gestational hypertension (Table S1). Chronic hypertension predates
Table 3. Grading systems for assessing the strength of recommendations.
PRECOG PRECOG II
(grade given
according to
level of evidence
recommendation was
based on)
Canadian Task Force
For Preventive
Health Care
NICE
(intervention
studies)
NICE
(accuracy
of
diagnostic
tests ESC
NVOG
(methodological
quality of
studies)
NVOG (level of
evidence
of conclusions) GRADE
Grade A A (good evidence to
recommend)
– – Class I (treatment/
procedure
beneficial, useful,
effective)
– – Strong
Grade B B (fair evidence to
recommend)
– – Class II (evidence
conflicting
about usefulness/
efficacy)
– – Weak
Grade C C (conflicting evidence,
does not allow to make
recommendation)
– – Class IIa (evidence
in favour
of usefulness/effi-
cacy)
– –
Grade D D (fair evidence to
NOT recommend)
– – Class IIb (useful-
ness/efficacy
less well estab-
lished)
– –
GPP E (good evidence to
NOT recommend)
– – Class III (treatment/
procedure
NOT useful/effec-
tive)
– –
I (insufficient evidence,
does not allow to make
recommendation)
– – – –
doi:10.1371/journal.pone.0113715.t003
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pregnancy or is documented before 20 wks. One CPG specifies that this must be
essential (i.e., without known cause) [QLD]) and three list either secondary causes
and/or co-morbid conditions that would influence decisions about BP control
[AOM, QLD, SOGC]. Gestational hypertension is new hypertension that develops
at or after 20 wks; although implied by all CPGs, some specify that there must be
neither proteinuria [QLD] nor other features of pre-eclampsia (N52) [ACOG,
NICE] Three CPGs specify that BP must return to normal postpartum, at 12 wks
(N52) [QLD, NVOG] or at an unspecified time [ACOG].
All CPGs define pre-eclampsia as gestational hypertension with proteinuria
which is more often a mandatory criterion (N55) [PRECOG, PRECOG II, WHO,
NICE, NVOG] than not (n54) [AOM, QLD ACOG, SOGC] (Tables S1 and S2).
Two CPGs specify that the proteinuria must resolve after delivery [PRECOG,
PRECOG II]. Although four also include gestational hypertension with one/more
systemic feature of pre-eclampsia, there is no consistency with regards to those
features that include fetoplacental abnormalities and/or maternal symptoms,
signs, and abnormal laboratory findings [ACOG, AOM, QLD, SOGC]. The most
common maternal manifestations listed are: headache/visual symptoms (N54
CPGs), right upper quadrant/epigastric abdominal pain (N53), severe hyper-
tension (N52), eclampsia (N52), pulmonary oedema (N53), low platelets
(N54), elevated serum creatinine (N54), and elevated liver enzymes (N54); only
one CPG specifies hyperreflexia. Fetal manifestations of pre-eclampsia are
specified by three CPGs, all of which list IUGR (not defined) (N53) and
abruption without evidence of foetal compromise (N53); one specifies stillbirth.
‘Superimposed’ pre-eclampsia is not clearly defined. Three CPGs do not
address this at all, and six define it variably as worsening hypertension (N53)
[AOM, ACOG, SOGC], new/worsening proteinuria (N53) [AOM, ACOG,
SOGC] or one/more other systemic features (N54) [NVOG, AOM, ACOG,
SOGC]. ‘Worsening’ hypertension is defined clearly by two CPGs as either: (i) a
sudden increase in BP or the need to increase antihypertensive dose [ACOG], or
(ii) the need for three antihypertensive medications for BP control at§20 weeks
[SOGC]. Proteinuria is a mandatory criterion according to ACOG (Table S1).
‘Severe’ pre-eclampsia is defined by most (7/9) CPGs, but there is little
consistency. Heavy proteinuria is included by some (N53) [WHO, NVOG,
AOM], but specifically excluded by others (N52) [ACOG, SOGC]. Five CPGs
define end-organ complications of severe pre-eclampsia; the most common
maternal are: headache/visual symptoms (N55 CPGs), right upper quadrant/
epigastric abdominal pain (N54), severe hypertension (N55), eclampsia (N52),
pulmonary oedema (N53), low platelets (N54), renal insufficiency (N53), and
elevated liver enzymes (N53); these mirror the diagnostic criteria used in some
guidelines. Fetal manifestations of pre-eclampsia are specified by three CPGs, all
of which list stillbirth and none of which specify abruption without evidence of
fetal compromise; IUGR is included by WHO and SOGC, but specifically
excluded by ACOG. The SOGC ‘severity’ criteria are indications for delivery, and
include some features that in other CPGs: (i) define pre-eclampsia but not severe
pre-eclampsia (e.g., stroke), (ii) define both pre-eclampsia and severe
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pre-eclampsia (e.g., eclampsia, pulmonary oedema, platelet count ,1006109/L,
and acute kidney injury), or (iii) define neither pre-eclampsia nor severe pre-
eclampsia but are widely regarded as indications for delivery (e.g., uncontrolled
severe hypertension).
In the three CPGs that specify that proteinuria is mandatory to define pre-
eclampsia [WHO, NICE, NVOG], severe pre-eclampsia is the development of:
(i) pre-eclampsia at ,34 wk [WHO], or (ii) one/more features of end -organ
dysfunction that is either not defined [WHO and NICE] or listed as ‘‘symptoms’’
[NVOG], heavy proteinuria [NVOG, WHO], or severe hypertension [NVOG,
WHO] (Table S2).
In the four CPGs that do not include proteinuria as mandatory to define pre-
eclampsia [AOM, QLD ACOG, SOGC], severe pre-eclampsia is the development
of: (i) pre-eclampsia at ,34 wk [AOM], (ii) proteinuria plus one/more features
that alone would signify pre-eclampsia (cerebral/visual disturbances, pulmonary
oedema, platelet count ,1006109/L, renal insufficiency, or elevated liver
enzymes) [ACOG], or (iii) one/more features of end-organ dysfunction described
as: heavy proteinuria [AOM], one/more features of HELLP [QLD], new persistent
and otherwise unexplained right upper quadrant/epigastric abdominal pain
[ACOG], severe hypertension [AOM ACOG], or those dysfunctions requiring
delivery [SOGC] (Table S2).
Eclampsia is consistently defined by new onset and otherwise unexplained
seizures in the setting of pre-eclampsia (N55 CPGs) [NICE, QLD, WHO, ACOG,
SOGC]. No guideline defines the widely used term, ‘imminent eclampsia’.
Prediction (Table S3)
Screening only by clinical risk markers is recommended (N53 CPGs, 0 high
rating), with no guideline recommending routine use of biomarkers or
ultrasonography. The actual risk markers used were not reviewed.
Table 5 presents information from the two guidelines that present recurrence
risks for gestational hypertension and pre-eclampsia according to their occurrence
in the prior pregnancy [NICE, SOGC].
Prevention (Table S4)
Women at low risk of pre-eclampsia are recommended NOT to restrict dietary
salt [N54, 0 high rating] [ACOG, NICE, SOGC, WHO], or take vitamins C and/
or E (N54, 3 high rating) [ACOG, NICE, SOGC, WHO] or diuretics (N53, 1
high rating) [NICE, SOGC, WHO]. Of interest, few guidelines commented on
calcium supplementation (1–2 g/d) if women have low calcium intake (N52, not
recommended, 1 high rating) [WHO, SOGC] or low-dose aspirin (1, not
recommended, 1 high rating) [SOGC].
Women at increased risk of pre-eclampsia are recommended to take calcium
supplementation (1–2.5 g/d) if they have low calcium intake (N53 CPGs, 2 high
rating) [AOM, WHO, SOGC], and low-dose aspirin (60–162 mg/d) (N55 CPGs,
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2 high rating) [ACOG, AOM, NICE, SOGC, WHO]. Aspirin is recommended to
be taken from early pregnancy (N55, 1 high rating) [ACOG, AOM, NICE, SOGC,
WHO] until delivery (N53, 1 high rating) [AOM, NICE, SOGC]. These women
are recommended NOT to restrict dietary salt (N53, 0 high rating) [ACOG,
NICE, WHO] or take vitamins C and/or E (N54, 3 high rating) [ACOG, NICE,
SOGC, WHO].
Treatment (Table S5)
Bed rest
No consistent (or high rating) recommendations are made about bed rest by type
of HDP (N54 CPGs) [NICE, WHO, ACOG, SOGC]. Bed rest is NOT
recommended for any HDP with two exceptions: gestational hypertension for
which bed rest in hospital (vs. unrestricted activity at home) may be useful
[SOGC], and severe pre-eclampsia which is excluded from the ACOG rest
recommendations.
Admission to hospital
The only indication for hospital admission that is consistently recommended is
severe hypertension (N55 CPGs, 0 high rating) [QLD, NICE, PRECOG, SOGC].
Antihypertensive therapy
Six CPGs discuss antihypertensive therapy [ACOG, QLD, NICE, NVOG, SOGC,
WHO].
Severe hypertension should be treated (N56, 1 high rating), but BP goals to
achieve vary: ,150/80–100 mmHg [NICE] or ,160/110 mmHg (N54, 1 high
rating) [QLD, ACOG, SOGC] for all but women with chronic hypertension,
for whom ACOG recommends achieving a BP,160/105 mmHg [ACOG].
Recommended drugs of first choice are intravenous (iv) labetalol (N53, 1 high
rating for iv) [NICE, NVOG, SOGC], oral nifedipine (N53, 1 high rating) [NICE,
NVOG, SOGC], and iv hydralazine (N52, 1 high rating) [NICE, SOGC]; two
Table 5. Risks of recurrence for GH and PET reported in the NICE and SOGC guidelines.
Second pregnancy* {
First/prior pregnancy GH PET
GH 16–47% (NICE) 2–7% (NICE)
Median 21% (SOGC) Median 4% (SOGC)
PET 13–53% (NICE) 16% for PET (NICE)¤ 1
Median 22% (SOGC) Median 15% (SOGC)
*Recurrence more likely in women with higher BMI, and when the prior PET was: of early onset, ‘‘severe’’, or complicated by eclampsia or HELLP syndrome
(SOGC).
{The following traditional PET risk markers for first occurrence do NOT influence recurrence: multiple gestation, change of partner, and long interpregnancy
interval (SOGC).
¤25% if complication of PET let to birth ,34 weeks (NICE).
155% if complications let to birth ,28 weeks (NICE).
doi:10.1371/journal.pone.0113715.t005
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CPGs leave the choice to the clinician [QLD, WHO]. MgSO4 should not be used
as an antihypertensive (N51, high rating) [SOGC].
Target BP for women with non -severe hypertension is variable (N54 CPGs, 0
high ratings), and dependent on associated co-morbidities and/or type of HDP.
For women with end-organ dysfunction that can be exacerbated by elevated BP,
treatment to BP,140/90 mmHg is recommended [NICE, SOGC]. For women
without target-organ damage, treatment targets are: (i) for any HDP, ,150/80–
100 mmHg [NICE], 130–159/80–105 mmHg [SOGC], or ,160/110 mmHg
[NVOG], (ii) for women with chronic hypertension, 120–159/80–104 mmHg
[ACOG], and (iii) for women with gestational hypertension or non-severe pre-
eclampsia, ,160/110 mmHg [ACOG]. Oral methyldopa (N54, 1 high rating)
[NICE, NVOG, ACOG, SOGC], oral labetalol (N54, 1 high rating) [NICE,
NVOG, ACOG, SOGC], and nifedipine (N54, 1 high rating) [NICE, NVOG,
ACOG, SOGC] are most commonly recommended, although SOGC also
lists ‘other calcium channel blockers’ as an option with a high rating.
Antihypertensives NOT to use are ACE inhibitors and ARBs (each N54, 0 high
rating).
For women with chronic hypertension who are taking antihypertensive therapy
and planning pregnancy, it is recommended that preconceptual counselling be
undertaken (N54) [NICE, QLD, NVOG, SOGC] and that this include discussion
of alternatives to ACE inhibitors and ARBs which should be stopped if
inadvertently taken in early pregnancy (N54) [NICE, NVOG, ACOG, SOGC].
Antenatal corticosteroids
Specific recommendations for women with HDPs are made by four CPGs, by
gestational age, time to delivery, and/or type of HDP. Although all recommend
steroids at ‘‘,34 wk’’, there is some imprecision in how that is defined: ‘‘to
34 wk’’ [NICE], ‘‘before 34 wk’’ [NVOG], #33+6 and #34+0 wk in the same
CPG [ACOG], and #34+6 wk [SOGC]. Three CPGs recommend antenatal
corticosteroids for HDPs that may require delivery within the next 7 days
[NVOG, NICE, SOGC]. Antenatal corticosteroids are recommended specifically
for all women with pre-eclampsia (N51 high rating) [SOGC], superimposed PET
(N51 high rating) [ACOG], or severe pre-eclampsia who are undergoing
expectant care (N51 high rating) or require delivery within the next 48 hr (N51,
0 high rating) [ACOG].
Corticosteroids are NOT recommended to improve clinical outcomes in
HELLP syndrome (N54, 0 high rating) [ACOG, NICE, SOGC, WHO], but one of
these CPGs [ACOG] suggested considering this therapy if an improvement in
platelet count would be useful.
Timing of delivery
Recommendations for delivery (and administration of antenatal corticosteroids, if
appropriate) focus on women with pre-eclampsia (N55 CPGs) [ACOG, NICE,
NVOG, SOGC, WHO]. Uncontrolled severe hypertension is the most widely
regarded maternal indication for delivery (and treatment) (N53, 0 high rating)
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[NICE, WHO, ACOG]. Expectant care is considered appropriate depending on
the type of HDP and gestational age, assuming that women and fetuses can be
appropriately managed and cared for when delivered.
Women with pre-eclampsia can be expectantly managed at ,34 wk (N53, 0
high rating) [NICE, ACOG, SOGC], but they should be delivered at term (N54, 1
high rating) [NICE, WHO, ACOG, SOGC]). If pre-eclampsia is severe, women
should be delivered if they are prior to fetal viability (N53, 1 high rating for
HELLP) [WHO, ACOG, SOGC] or if they are at term (N54, 1 high rating)
[NICE, WHO, ACOG, SOGC]. Women with gestational hypertension should be
delivered at term (N53, 0 high rating) [WHO, ACOG, SOGC]. There is no
consistent guidance for women with chronic hypertension.
Labour and delivery
Issues related to labour and delivery were addressed by 5/9 CPGs [ACOG, AOM,
QLD, NICE, SOGC]. Without fetal compromise, mode of delivery should be
based on the clinical circumstances and usual obstetric indications (N54, 0 high
rating) [ACOG, QLD, NICE, SOGC]. If a vaginal delivery is planned, and the
cervix is unfavourable, cervical ripening should be undertaken (N52, 2 high
rating) [QLD, SOGC]. Active management of the third stage of labour is
recommended with oxytocin (N52, 2 high rating) [AOM, SOGC].
Magnesium sulphate (MgSO4) indications
MgSO4 is indicated for treatment of eclampsia (N56, 3 high rating) [NICE, QLD,
NVOG, WHO, ACOG, SOGC] and severe pre-eclampsia (N55, 3 high rating)
[NICE, NVOG, WHO, ACOG SOGC] although the ACOG CPG specified only
intrapartum and postpartum administration. There was less certainty about
recommending MgSO4 for non-severe pre-eclampsia (N53, 0 high rating)
[NVOG, ACOG, SOGC] although no CPG recommended against it.
Postpartum
Many guidelines made recommendations that immediately postpartum, BP may
increase (N53, o high rating) [NICE, ACOG, SOGC] and pre-eclampsia may
worsen or appear for the first time (N55, 0 high rating) [AOM, NICE, QLD,
ACOG, SOGC]. Antenatal antihypertensive therapy should be continued (N53, 0
high rating) [NICE, SOGC, WHO]; no guideline recommended that it be stopped
completely. Although the treatment of severe hypertension followed similar
recommendations to those for women before delivery (see ‘Antihypertensive
therapy’) (N54, 1 high rating) [NICE, WHO, ACOG, SOGC], treatment targets
for non-severe hypertension were generally lower: for women with chronic
hypertension, ,140/90 mmHg [NICE, SOGC] or ,150/100 mmHg [ACOG], for
women with GH, ,150/100 mmHg [NICE, ACOG], and for women with pre-
eclampsia, ,150/100 mmHg [NICE, ACOG] (none of high rating). CPGs
reflected the association between the HDPs and future health (with regards to
hypertension, renal disease, and other long-term cardiovascular disease), and
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suggested lifestyle counselling) (N55, 1 high rating for achieving a health BMI
among obese women) [ACOG, AOM, QLD, NICE, SOGC].
Other
Some CPGs present detailed information about an area not covered by others and,
therefore, were not discussed above. Examples include detailed information about
anaesthesia/analgesia [SOGC], maternal monitoring and transfer of care from
midwifery to secondary care settings [PRECOG, PRECOG II, NICE], or
postpartum transfer back to the community [NICE] (Table S5).
Discussion
Findings
We identified 13 CPGs that published recommendations about the diagnosis,
classification, prevention and treatment of the HDPs. Four CPGs were assessed as
‘not useful’ to busy clinicians, based on text-only publication [DGGG, SOMANZ,
ASH] or limited text with only a few focused recommendations [ESC]. Analysis of
the nine remaining CPGs revealed few consistencies and/or high rating
recommendations. Consistency was seen for the definitions of hypertension,
proteinuria, chronic and gestational hypertension. Consistency and high ratings
(by at least one CPG) was seen for: (i) the preventative strategies of calcium (in
the setting of low intake) and low-dose aspirin for women at increased risk of pre-
eclampsia, and neither vitamins C and E or diuretics; (ii) antihypertensive
treatment of severe hypertension; (iii) MgSO4 for eclampsia and severe pre-
eclampsia; (iv) antenatal corticosteroids at ,34 wks when delivery is probable
within the next seven days; (v) delivery for women with severe pre-eclampsia who
do not yet have a viable fetus and for those with any pre-eclampsia at term; and
(vi) active management of the third stage of labour with oxytocin.
Notable inconsistencies, illustrative of a lack of consensus, were in areas
well reported by CPGs that differed nevertheless in their recommendations:
(i) definitions of pre-eclampsia and in particular, severe pre-eclampsia and
superimposed pre-eclampsia that reflect our evolving understanding of the
multisystem nature of the disease; (ii) target BP among women with non-severe
hypertension, regardless of the HDP; (iii) timing of delivery for women with
pre-eclampsia and severe pre-eclampsia; (iv) MgSO4 for non-severe
pre-eclampsia, and (v) postpartum monitoring for maternal safety and
improvement of long-term cardiovascular health. These are areas requiring
further research and consensus-building for optimising management of a high risk
group of women.
Some guidelines covered areas neglected by others, and those CPGs could be
useful sources of specific information. Notable examples include post-delivery
discharge planning for transfer of care [NICE] and obstetric anaesthesia for the
HDPs [SOGC].
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How our findings fit with the published literature
We are aware of only one review of CPGs for pregnancy hypertension [45]. The
AGREE II instrument was used to evaluate methodological quality; CPGs scored
highest in ‘‘clarity of presentation’’ and lowest in ‘‘editorial independence’’,
consistent with our findings. Between-CPG differences in the number and
extensiveness of recommendations were identified, but recommendation content,
similarities and differences between guidelines were not explored.
The 2014 position statement from the International Society for the Study of
Hypertension in Pregnancy (ISSHP) endorses areas of consistency within
published CPGs [46]. Of note, ISSHP endorses a definition of pre-eclampsia that
does not require proteinuria, but can be made based on maternal end-organ
involvement and/or fetal IUGR. Uniquely, ISSHP does not support a distinction
between severe and ‘‘mild’’ pre-eclampsia which, ‘‘…should be considered as one
that is at anytime capable of being severe and life-threatening for mother and
baby’’. Superimposed pre-eclampsia should not be diagnosed based on a rise in
BP alone. Gestational proteinuria is mentioned specifically as potentially
signifying evolving pre-eclampsia or underlying renal disease. All women with
pre-eclampsia should be admitted to hospital, at least initially. MgSO4 is
advocated for all women with pre-eclampsia in low-and-middle-income
countries. Particular emphasis is placed on the importance of recognising ‘white
coat’ hypertension, the promising future of biomarkers as diagnostic and/or
prognostic tools [47], and the importance of each unit having its own written
policies to promote uniform care, the outcomes of which can be monitored.
Two of the CPGs presented ‘auditable’ standards [33, 43], but their complexity
in one would be difficult to operationalise [NICE] (http://www.nice.org.uk/
guidance/qs35) and only one criterion is presented in the other CPG [WHO]. Our
review suggests that where there is consistency between CPGs, there is the
potential for standardisation of both: definitions that will support research efforts
[48, 47], and quality of care criteria, particularly if the between-CPG differences in
quality of evidence/strength of recommendation can be resolved.
The AGREE II tool is the standard for assessing the quality of published CPGs
[13]. However, it has never been shown to improve guideline uptake or
implementation [8], and use of the AGREE II presents some difficulties. First,
AGREE II lists many criteria and few CPGs in our review scored highly on some
or most domains, which may reflect space limitations in the journal of
publication, rather than guideline quality. Second, AGREE II scores do not reflect
important usability issues, such as the length of the CPG document and
appendices/evidence tables (extensive for the NICE guideline), number of
formulated recommendations, and presentation of the grading of the evidence
relative to the recommendation, or lack of assessment of the strength of the
recommendation (absent from AGREE II), all of which must be considered when
evaluating how easy guidelines would be to use clinically. Although we did not
exclude any CPGs based on their AGREE II domain scores, the four CPGs deemed
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‘not useful’ for busy clinical practice did receive the lowest scores [ASH, DGGG,
ESC and SOMANZ].
Strengths and limitations
The strengths of our review include: a comprehensive literature search by an
information technology specialist, inclusion of CPGs published in the last 10 years
and in any of four languages, and the systematic summary of the diagnostic
criteria and stated recommendations for the prevention of pre-eclampsia and
treatment of the HDPs, incorporating quality of evidence and strength of
recommendations. Although it is recommended that guidelines be updated every
3–5 years [49–51], the time consuming work of developing CPGs could mean that
some guidelines are not updated as frequently as recommended and in our review,
limiting to publication within the last 5 years would have excluded 4/13 CPGs.
Our review has limitations. A potential selection bias exists in the fact that only
CPGs written in English, German, French and Dutch were included; however, we
excluded only two CPGs (in Spanish [28, 29]) for this reason; the French CPG
excluded was because it was available only by purchase for a significant sum [26].
The CPGs were assessed by two appraisers; this approach meets the minimum
number of appraisers advised by AGREE II, but some authors have used more. As
our focus was on the clinician, we did not extract and compare information
available only from guideline text, some of which runs to 288 pages (even without
appendices or evidence tables) [NICE] and none of which has associated ‘strength
of recommendation’ that would aid the reader in deciding whether to comply or
not. Finally, discrepancies in grading of evidence between different systems for the
same recommendation were noted.
Conclusions
The existing CPGs that inform care for women with a HDP have areas of
consistency with which clinicians and researchers can work to develop auditable
standards, and areas of inconsistency that should be addressed by future research.
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